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Summary
Human CD141+ (BDCA-3+) dendritic cells (DCs) are specialized to cross-
presentation and, thus extensively studied for developing DC-based therapy 
against cancer. A series of attempts was made to generate CD141+ DCs from 
cord blood CD34+ hematopoietic progenitors to overcome a practical limitation, 
in vivo rareness. However, in vitro differentiation of CD141+ DC needs to be 
further investigated. In the present study, I identified CD141 expression in the 
well-known culture system that generates DCs from CD14+ monocytes in 
presence of GM-CSF and IL-4. After 8-days of the culture, CD141 was 
detected only on the cells which adhered to the bottom of the culture plate. The 
attached cells exhibited a typical feature of immature monocyte-derived DCs 
(moDCs), except for higher CD86 expression, more dendrites, and higher 
granularity compared to those which did not attach. Additional 3 days of culture 
further increased CD141 expression in the cells retaining adhesion, which 
partially expressed CELC9A. Indeed, they exhibited relatively effective uptake 
of dead cells. Interestingly, the attached moDCs differently responded to 
polyinosinic:polycytidylic acid (poly I:C) stimulation as well as  the mixed 
lymphocyte reaction. Collectively, in vitro generation of human CD141+ DCs 
from CD14+ monocytes will contribute to further investigation into yielding 
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I. Review of Literature
1. Human monocyte-derived DC 
1.1 Monocyte
Monocytes are a group of immune cells that originate in bone marrow and 
are released into peripheral blood, where they circulate for several days [1]. 
Monocytes represent 5-10% of peripheral leucocytes and are probably best 
known for serving as a systemic reservoir of myeloid precursors that are needed 
for the renewal of tissue macrophages and dendritic cells [2]. In humans, 
monocytes have been divided into three subtypes based on relative surface 
expression of LPS co-receptor CD14 and FCγ III receptor CD16 [3] (Fig. 2). 
Classical monocytes (CD14++CD16-) are the major population of human 
monocytes (~80%). the remaining population (~20%) of human monocytes are 
further subdivided into two subtypes. The more abundant non-classical subsets 
(CD14+CD16++) are characterized by very low expression of surface CD14 and 
high levels of CD16, whereas intermediate subset (CD14++CD16+) express high 
levels of CD14 molecules [4].
1.2 In vitro-derived moDCs
Human DC function has been obtained from DC derived from monocytes 
differentiated in vitro by culture with GM-CSF and IL-4 over the past two 
decades [1, 5]. In vitro culture system provides a versatile environment for 
skewing DC with potent cytotoxic T lymphocyte response (CTL) [6], Th1 [7], 2 
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[8], 17[9] or regulatory functions [10] by adding and substituting cytokines, 
growth factors, and other stimuli to culture. These in vitro derived moDCs have 
been extensively used in the clinic, mostly as vaccines to induce anti-tumor 
immune responses in cancer patients [11]. Although the physiological relevance 
of moDCs is unclear, the similarity of these cells with DCs found in human 
inflamed tissues suggests them to be most closely related to inflammatory DCs 
[12]. However, in vitro cultured moDCs are heterogeneous. Some of them 
attached on the bottom of culture plate were observed but not reported about 
their characteristics although suspended one is generally recognized as 
immature moDCs [1, 5, 13]. Therefore, in vitro cultured moDCs are still in need 
for further investigation.
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2. Human CD141+ dendritic cell 
2.1 Introduction
Human CD141 (BDCA3)+ DCs are found in various tissues such as blood, 
tonsil, lymph nodes, spleen, skin, liver, lung, and intestine [14-16]. CD1c 
(BDCA1)+ DCs, the other subset of conventional dendritic cells (cDCs), 
represent by far the most predominant cDC subset in human blood, whereas 
CD141+ DCs consist of a minor blood population (Fig. 1). They exist 
approximately 0.03% in peripheral blood mononuclear cell (PBMC) [3, 16, 17]. 
Although this rareness was limitation for detailed functional analysis of this 
subset, transcriptional analysis suggests high correlation of function between 
human CD141+ DCs and their mouse CD8+/CD103+ counterparts [18, 19]. 
2.2 Characterization of CD141+ DCs
CD141 is a cell surface-expressed transmembrane glycoprotein, known as 
thrombomodulin or BDCA3. Together with BDCA1 (CD1c), BDCA2 (CD303)
and BDCA4 (CD304), CD141 is generally used to classify human DC. 
However, CD141 expression is not selectively expressed by the CD141+ DC 
subset, since intermediate expression of CD141 has also been found on 
monocytes and other DC subsets, such as blood plasmacytoid DCs (pDCs), skin 
DCs [18, 20, 21]. Although the typical CD141+ DC subsets express higher 
levels of CD141 than other DCs, it is important to use CD141 in combination 
with 
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Figure 1. The subsets of DCs in human PBMC. 
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distinct markers that are unique to CD141hi DC subsets to assure selection of 
CD141+ DCs. CD141+ DCs uniquely express the CLEC9A (c-type lectin 
domain family 9A), known as DNGR-1, which is damage-associated molecular 
pattern (DAMP) receptor that senses necrotic cells [22, 23]. In addition, they 
express chemokine receptor, XCR1 and preferentially induce optimal cytotoxic 
T lymphocyte (CTL) responses through the interaction of XCR1 with XCL1 
selectively expressed on CD8+ T cells [24-26]. DEC205, endocytotic receptor, 
also expressed high levels on CD141+ DCs recognizes dead cells [16, 27]. 
CD141+ DCs specifically express cell adhesion molecule 1 (CADM1), also 
called as nectin-like protein 2 (Necl2) [28]. Although CADM1 is expressed on 
various cell types, its expression among blood leukocytes is restricted to 
CD141+ DCs [29]. Furthermore, CD141+ DCs express significantly high level 
of toll like receptor (TLR) 3 [16]. Needless to say that TLR3 ligation by 
polyionsinic:polycytidylic acid (polyI:C) is commonly used for in vitro
stimulation of CD141+ DCs.
2.3 The role of CD141+ DCs in T cell responses
One of the first studies on the function of CD141+ DCs demonstrated that 
blood CD141+ DCs are superior to produce IL-12p70 in response to stimulation 
with a cytokine cocktail of polyI:C, interferon (IFN)γ, tumor necrosis factor 
(TNF)a, IFNα, interleukin (IL)-1β compared to CD1c+ DCs [16]. In addition, 
blood CD141+ DCs were reported to produce IFNα, IFNβ, IL-6, IL-8, TNFα, 
and CXCL10 in response to polyI:C [16, 30]. The production of these cytokines
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by CD141+ DCs upon stimulation suggests that these cells could induce Th1 
responses, which play a key role in anti-viral immune responses. Co-culture of 
CD141+ DCs with allogeneic naïve CD4+ T cells induced high production of 
the Th1 cytokines IFNγ and IL-2 [16, 17]. Furthermore, CD141+ DCs induced 
high proliferation of allogeneic naïve CD4+ T cells. However, many studies 
showed it is not clear the plasticity of CD141+ DCs in terms of Th2-skewing 
[31] and tolerogenic functions [20, 32] in addition to their Th1-inducing ability.
2.4 Cross-presentation of CD141+ DCs
DCs are specialized in capture antigen and present antigenic molecule to T 
cells. The majority of antigens derived from endogenously synthesized proteins 
presented by DCs in MHC class I, however, DCs have the capacity to cross-
present exogenous-derived antigen in MHC class I molecules. This pathway 
actives CD8+ T cells which play a key role in the immune control of tumors and 
viral infections [33]. CD141+ DCs initially reported that they exhibit a 
specialized cross-presenting capacity because they were likely to be more 
efficient at cross-presentation of soluble and cell associated antigens than other 
DC subsets [17, 25]. However, recent studies showed that other DCs are able to 
cross-present soluble antigens as efficient as CD141+ DCs [34-36]. Although 
controversial results were reported about the efficiency of CD141+ DCs at 
cross-presentation of soluble antigens, CD141+ DCs exhibit a specialized 
mechanism to transfer antigens from late endosomes and lysosomes to the 
cytosol [37] and superiority at the uptake and cross-presentation of necrotic 
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cell-associated antigens [16, 17, 25, 36]. CLEC9A and TLR3 were shown to 
mediate and enhance cross-presentation of dead cell-associated antigens [22, 38, 
39]. In addition, XCR1 may contribute to activate CD8+ T cells upon 
presentation of exogenous antigens on MHC class I by CD141+ DCs, which can 
enhance cellular interaction with CD8+ T cells by the XCR1-XCL1 axis [24, 
25].
2.5 Development of CD141+ DCs
The development of CD141+ DCs is poorly defined because of their low 
abundance and difficult isolation. Nevertheless, possibility to generate CD141+
DCs in vitro has recently activated research into the development of this subset 
[17, 28, 40]. In vitro systems have been described that generate CD141+ DCs 
from HPC [17, 28]. In the system human lineage-negative cord blood cells, 
including HPC, were cultured under the stem cell factor (SCF), Flt3L, IL-3, and 
IL-6 and then differentiated with Flt3L, GM-CSF, and IL-4 which induced the 
small population of CD141+ DCs [17]. The protocol described by other group 
involved thrombopoietin (TPO), SCF, Flt3L, IL-6 and yielded much higher 
numbers of CD141+ DCs [28]. Although these culture systems involve Flt3L, 
the requirement of Flt3L in CD141+ DC development remain to be elucidated. 
In addition, GM-CSF, a cytokine involved in development of peripheral DCs, 
may contribute to development of CD141+ DCs [41, 42]. Furthermore, the 
nature of precursors of CD141+ DCs in human needs to be further characterized. 
According to CD141+ DCs in vivo, it is likely that lymphoid tissue and 
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peripheral tissue CD141+ DCs derived from blood CD141+ DCs because blood 
CD141+ DCs not fully differentiated until reside in peripheral tissue like skin 
[18, 34]. On the other hand, recent studies describe that the heterogeneous 
precursors in blood are pre-committed to become either CD1c+ or CD141+ DCs 
[43, 44]. Therefore, roles for cytokines and precursors in development of 
CD141+ DCs remain to be determined.
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II. Introduction
Dendritic cells (DC), as one of the professional antigen-presenting cells, 
process antigenic materials and present epitopes to T lymphocytes [45, 46], 
bridging between the innate and the adaptive immune system [47, 48]. As well 
studied, exogenous antigens, such as extracellular pathogens and tumor, 
engulfed by DC are enzymatically processed into peptide fragments fitting onto 
major histocompatibility complex (MHC) II which interact with T-cell receptor 
of CD4+ helper T cells [49]. However, in addition to this conventional 
processing, DCs are able to cross-prime CD8+ T cells by alternatively loading 
the endocytosed antigens on MHC I, eliciting the clearance of the damaged 
cells including tumor cells [49]. This cross-priming ability allowed DC as a 
prime candidate that deserves intense investigation for the development of anti-
cancer vaccine [50]. In practice, clinical trials of DC-based immunotherapy 
promised a long-term survival of melanoma, prostate cancer, primary brain 
tumors (glioma), and renal cell cancer patients [11, 51, 52]. 
Less than two decades ago, researchers found that human CD141+ DCs are 
counterpart of mouse CD8α+ lymphoid DC or CD103+ non-lymphoid tissue 
equivalent, both of which are specialized in cross-presentation [17-19]. In 
particular, human CD141+ DCs highly express CLEC9A, XCR1, and TLR3, 
which play unique function in cross-priming [16, 17, 25]. They are prone to 
induce cytotoxic T lymphocyte (CTL) responses through interaction of XCR1 
with XCL1 selectively expressed on CD8+ T cells [24-26], as well as to sense 
10
and present necrotic cell bodies via CLEC9A, c-type lectin receptor [16, 17]. 
Moreover, CD141+ DCs could be strongly activated by polyI:C, toll like 
receptor 3 (TLR3) agonist, as assessed by expression of costimulatory 
molecules such as CD80 and CD40 and production of inflammatory cytokines 
such as IL-6 [16, 18, 53]. However, there are discrepancies between the initial 
reports characterizing human CD141+ DCs and still, many questions about their 
ontogeny and distribution need to be answered.
A major obstacle to investigating CD141+ DC biology and for further 
applying them to the therapeutic is their paucity, ‘in vivo rareness’. [54, 55].
There are a series of attempts to overcome this problem by in vitro generating 
CD141+ DCs from cord blood (CB) progenitors [17, 28]. According to the 
published protocol, CD141+ DCs could be differentiated into CD34+ cells 
isolated from CB, then cultured with five different cytokines for 7 days, 
followed by additional culture for 13 days with some of the cytokines replaced 
[17]. It was recently reported that a modification of this protocol advanced in 
yielding the more cell numbers [28]. However, fundamental limitation of CB as 
resources strongly demands further investigation for in vitro generating CD141+
DCs.
In the present study, I found that CD141+ DCs could be generated from adult 
peripheral blood CD14+ monocytes, cultured with GM-CSF and IL-4 for 8 days. 
[1, 13, 46] Among these monocyte-derived dendritic cells (moDC), the cells 
attached on the bottom of culture plate [5] expressed high CD141 than 
compared to other cells that loosely attached or suspended. The attached 
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CD141+ moDCs partially expressed CLEC9A and performed dead-cell uptake 
effectively compared to the others. They exhibited increase of costimulatory 
molecules and cytokines such as IL-6 in response to polyI:C treatment. In 
addition, they did not activate allogeneic naïve T cells in mixed lymphocyte 
reaction. These data suggested that CD14+ monocytes in adult peripheral blood 
could be an alternative source to obtain in vitro generation of CD141+ DCs for 
clinical application. 
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III. Materials and methods
Ethical statement
Normal adult blood samples were anonymously provided by the Blood 
Center of Korean Red Cross, Seoul under the approval of the Institutional 
Review Board of Korean Red Cross and the agreement for research purpose. 
The written informed consent from blood donors with respect to taking blood 
samples for research purposes was obtained and approved by the Ethics 
Committee of Korean Red Cross. All experimental procedures using human 
blood were performed under the approval of the Institutional Review Board at 
the Seoul National University (IRB no. E1702/001-001). Data were all analyzed 
anonymously.
Isolation of human monocytes
Peripheral blood mononuclear cells (PBMC) were purified from normal adult 
human blood by density gradient centrifugation using Ficoll-Paque Plus™ (GE 
Healthcare, Life Sciences). CD14+ monocytes were isolated from the PBMC 
using the BD IMagTM anti-human CD14 antibody, a magnetic bead-based 
positive selection kit (BD Biosciences). As soon as isolated, the cells were 
washed with RPMI 1640 more than two times and used immediately for further 
experiments. CD14+ monocytes are routinely obtained with above 95% purity, 
verified by flow cytometry. 
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CD14+ monocyte culture
CD14+ monocytes were cultured in RPMI 1640 containing heat-inactivated 
10% (vol/vol) FBS and 1% (vol/vol) antibiotics/antimycotic solution (all from 
Invitrogen) at 37°C under 5% CO2. For generation of moDCs, the cells were 
incubated at 1 ~ 2 × 106 cells/ml for 8 days with 500 U/ml rhIL-4 and 800 U/ml 
rhGM-CSF (all from JW CreaGene Inc.). Fresh media containing rhIL-4 and 
rhGM-CSF were added by half of the initial volume every 3 days. Unless 
indicated otherwise, the cells were split into three different phases (suspended, 
semi-attached, and attached cells) after 8 days of the culture and then directly 
used for analysis or further cultured separately for 3 days. In our experimental 
setting, suspended cells (Sus) were obtained by directly collecting the culture 
media, and then semi-attached cells (Sem), by adding and gently washing with 
PBS. Finally, attached cells (Att) were obtained after incubation with cell 
dissociation buffer (Invitrogen) for 6 min.
Wright–Giemsa staining
CD14+ monocyte culture was performed in the cell culture slide (SPL) for 
moDC generation, as above mentioned. The cells except for the attached cells 
were diluted at 2×105 cells/ml in 4% paraformaldehyde and used for the 
cytospin at 1100 rpm for 10 min. The slides were air-dried for 15 min, fixed 
and stained with Differential Quik Stain Kit (Polysciences, Inc.). Images were 
taken with an OLYMPUS CKX58 microscope.
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Flow cytometry
The cells were incubated with antibodies at 4 °C for 20 min in staining buffer 
(1 × PBS containing 0.1% BSA and 0.1% sodium azide). For intracellular 
staining, the cells were fixed, permeabilized with an intracellular fixation and 
permeabilization buffer set (eBioscience) according to the manufacturer’s 
instructions, and stained for TLR3. Samples were acquired on Canto II (BD 
Biosciences) and data were analyzed with FlowJo software (TreeStar). 
Antibodies used for flow cytometric analyses were fluorochrome-labeled mAbs 
against human CD86 (IT2.2), CD207 (10E2), CD1c (L161), HLA-DR (L243), 
CD16 (3G8), CD1a (HI149), CD64 (10.1), CD209 (9E9A8), CD326 (9C4), 
CD141 (M80), CD11b (ICRF44), (67A4), CD15 (W6D3), CD163 (GHI/61), 
CD80 (2D10), LAP (TW4-2F8), CD273 (24F.10C12), CD274 (29E. 2A3), 
CD284 (HTA125), CD282 (TL2.1), CD40 (5C3), CD83 (HB15e), Siglec-8 
(7C9), CD25 (M-A251), TLR3 (TLR3.7), CLEC9A (683409), XCR1 (1097A) 
(from BD Biosciences, eBioscience or R&D systems). 
Poly I:C stimulation 
poly I:C (InvivoGen) were added at 10μg/ml on 11 days of the CD14+
monocyte culture (as mentioned above). After 16h of culture, cells were 
analyzed by flow cytometry, or after 1 day of culture, the supernatants were 
collected to detect cytokines. 
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Mixed lymphocyte reaction
CD4+ T or CD8+ T cells were isolated from PBMC with BD IMagTM anti-
human CD4 antibody or anti-human CD8 antibody, respectively. Isolated T 
cells were labeled with CTV (2.5μM) and then co-cultured for 6 days with 
moDCs pre-incubated in the presence or absence of 10μg/ml poly I:C for 16 h.
The ratio of moDCs to T cells was 1:10. Allogeneic T cell proliferation and 
activation was assessed by flow cytometry.
Dead cell uptake
Dead cell uptake was performed as described previously with modification 
[17]. Cryopreserved autologous PBMC were thawed and heat killed (90ºC, 
30min) then labeled with CFSE. Dead cells were added to moDCs at 1:1 ratio 
for 2 h at 4°C or 37°C. For flow cytometric analysis, cells were stained for 
HLA-DR and the percentage of CFSE+HLA-DR+ cells was calculated by 
subtracting the frequency of positive events at 4°C (binding) from the 
frequency at 37°C (binding + uptake).
Enzyme-linked immunosorbent assay (ELISA)
Human IL-6, TNF-α, IL-2, IFN-γ, IL-17 in the culture supernatants were 
measured by using DuoSet ELISA kits (R&D Systems, USA) according to the 
manufacturer’s instruction. Optical density was measured by VersaMax ELISA 
Microplate Reader (Molecular Devices, USA) at wavelength 450 nm.
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Statistical analysis
The mean value ± standard deviation was determined on the basis of at least 
3 different blood samples. All the experiments were performed at least three 
times with different blood samples. All the data are representative or 
independent experiments yielding similar results. For comparison of means 
between two groups, the data were analyzed using two-tailed paired student’s t-
test and considered statistically significant when p-value was less than 0.05. For 
multiple group comparison, one-way ANOVA followed by a Friedman test and 
the results were corrected by Dunn’s multiple comparison test. A P-value of less 
than 0.05 was considered significant. All statistical analyses were performed 
using GraphPad Prism 5 version 5.01 (GraphPad Software, USA).
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IV. Results
1) Three different forms of moDCs after the differentiation of peripheral 
blood CD14+ monocytes
moDCs obtained from monocyte culture in the presence of GM-CSF and IL-
4 have been widely used in human DC studies [5, 13]. These moDCs were
observed to take attached, semi-attached, or suspended forms in the culture 
condition [5], among which the last is generally recognized as an immature 
human moDCs [5, 56]. However, the attached or semi-attached cells are not 
well investigated, with a superficial understanding of heterogeneity of moDCs. 
Thus, I distinguished the three forms of moDCs, based on their adhesive 
capacity (Fig. 2A) as explained thoroughly in the Materials and Methods. This 
protocol allowed us to gain consistently app. 0.56 × 106 of attached cells (Att) 
and 0.42 × 106 of semi-attached cells (Sem) from 1 × 107 of CD14+ monocytes 
(Fig. 2B). The attached and semi-attached cells consisted of app. 20 % and 12 % 
of the total moDCs (Fig. 2C), respectively. As previously reported [5, 56], 
suspended cells were the major population. I stained cells with Wright–Giemsa 
solution and found that the three forms of cells were similar in the cell-size, but 
the attached cells showed irregular shapes with dendrites elongated (Fig. 2D). 
FSC-A value of the attached cells was relatively higher than that of the others 
(Fig. 2E), which is seemingly attributed by their dendrites (Fig. 2D). Their 
SSC-A value was also slightly greater than the others (Fig. 2E), indicating that 
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the attached cells exhibited somewhat higher internal-complexity. Collectively, 
these data suggested that CD14+ monocyte treated with GM-CSF and IL-4 for 8 
days yielded the attached cells having relatively larger with elongated dendrites.
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Figure 2. Three different forms of moDCs after the differentiation of 
peripheral blood CD14+ monocytes. CD14+ monocytes (1 x 107) were 
cultured with GM-CSF and IL-4 for 8 days. (A) To analyze each subset 
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supernatant from moDC culture was harvested for suspended cells (Sus) and 
PBS washing for collecting semi-attached cells (Sem). Then, attached cells (Att) 
on the bottom of plate were collected by using cell dissociation buffer. (B) 
Absolute numbers of three subsets of moDCs are shown. Results from twelve 
independent cultures for each DC subset are shown as individual line. To 
determine the significance, one-way ANOVA followed by a Friedman test 
corrected by Dunn’s multiple comparison test was performed on twelve 
independent cultures from twelve different donors. *p<0.05, **p<0.01, 
***p<0.001. (C) The proportion of three subsets of moDCs from twelve 
independent cultures. (D) Microscopy analysis of the morphology of Giemsa 
stained moDC subsets separated at the end of culture. Bar = 10 µm. (E) FSC-A 
and SSC-A level of three moDC subsets. One representative result of at least 
nine independent cultures is shown.
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2) Attached cells in monocyte culture are immature DCs which relatively 
express high CD141 and CD86
Next, to determine phenotypic traits of each type of cells obtained by our 
protocol, I examined the expression of surface molecules involved in T cell-
stimulatory/inhibitory, epithelia-interacting, bacteria-sensing, and migratory 
features of DC, as well as cell-identifying markers (Fig. 3A). CD64, CD14, 
CD15, CD163 and Siglec 8 were not expressed on the attached one (Fig. 3Ai), 
ruling out the possibility that they are monocytes, macrophages and 
granulocytes [3, 57-59]. Instead, the attached cells expressed typical molecules 
defining human myeloid DC subsets, such as CD11b, CD11c, CD1a and CD1c, 
at similar level with that of the semi-attached or suspended one (Fig. 3Aii) [60]. 
The expressions of almost all the functional molecules, which I analyzed, 
including TLRs, MHC classes, chemokine receptors and B7 families except 
CD86 were similar among the three forms, whereas, interestingly, CD141 and 
CD86 were considerably higher in the attached cells. Indeed, the mean 
fluorescence intensity (MFI) of CD141 and CD86 was significantly greater in 
the attached cells relative to those of the others (Fig. 3B), suggesting that the 
attached cells in the 8-day culture of monocytes in the presence of GM-CSF 
and IL-4 are immature moDCs selectively expressing relatively higher CD141 
and CD86.
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Figure 3. Attached cells in monocyte culture are immature DCs which 
relatively express high CD141 and CD86. CD14+ monocytes were cultured 
with GM-CSF and IL-4 for 8 days. (A) A variety of cell surface markers of 
three subsets (Att, attached; Sem, semi-attached; Sus, suspended) of moDCs 
were analyzed by using flow cytometry. (i, phenotype markers of macrophages, 
monocytes, and granulocytes; ii, specific molecules for DCs; iii, TLRs, MHC 
molecules, chemokine receptors and B7 families; iv, additional markers 
characterizing DCs). Isotype control staining is shown as a gray curve on each 
23
histogram. One representative result of at least four independent experiments in 
shown. (B) MFI of CD141 and CD86 on each subset. Results from twelve 
independent cultures for each DC subset are shown as individual line. To 
determine the significance, one-way ANOVA followed by a Friedman test 
corrected by Dunn’s multiple comparison test was performed on twelve 
different donors. *p<0.05, **p<0.01, ***p<0.001.
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3) Non-attached cells are not important to CD141 expression of the attached 
cells in GM-CSF/IL-4-driven culture system
Next, I sought to gain an insight into factors contribute to the generation of 
the attached cells and their CD141 expression. Of note, I could obtain the 
attached cells only after 1 day of the culture and, absolute number of the 
attached cells was gradually decreased (Fig. 4A). However, the preferential 
expression of CD141 and CD86 on attached cells was observed at the late phase 
of the culture (Fig. 4A). To determine whether the cells attached at 1-day 
culture could express CD141 and CD86 without subsequent influences by non-
attached cells, I discarded the cells floating in the supernatant of 1-day or 6-day 
culture and then supernatant was added back to the cells after washing with 
PBS (Fig. 4B). Interestingly, neither CD141 nor CD86 on the attached cells 
were not affected by discarding the non-attached cells, which suggested direct 
or indirect factors by non-attached cells are negligible to selective expression of 
CD141 and CD86 on the attached moDCs (Fig. 4C).
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Figure 4. Non-attached cells did not have an impact on CD141 expression 
on the attached cells in GM-CSF/IL-4-driven culture system. CD14+
monocytes were treated with GM-CSF and IL-4. (A) The cells were harvested 
and analyzed for the absolute number and the MFI of CD141 and CD86 on 
three types of moDCs at indicated days. Results from at least four independent 
cultures for each DC subset are shown as dot with bar overlays indicating SEM. 
To determine the significance, one-way ANOVA followed by a Friedman test 
corrected by Dunn’s multiple comparison test was performed on three different 
donors. *p<0.05, **p<0.01, ***p<0.001. (B) To exclude influence of non-
attached cells including suspended (Sus, blue) and semi-attached cells (Sem, 
green) ① supernatant containing Sus of 1-day or 6-day culture for moDCs was 
collected. ② The plate was washed with PBS and harvested, ③ which were
centrifuged at 1200 rpm for 5min. ④ Then, the supernatant excluding Suswas 
added back to the culture left with only attached cells (red). (C). Attached 
moDCs from control group (con) and the groups that non-attached cells 
discarded were harvested analyzed at 1- (1d) and 6-day (6d). MFI of CD141 
and CD86 were normalized with that of control group. Results with at least five 
independent experiments for each DC subset. 
27
4) Adhesive capacity is partially involved in CD141 expression of moDCs
To determine whether attached property affects the expression of CD141, I 
separated subsets at 8 days after the culture and then cultured for additional 3 
days (Fig. 5A). It was evidence that the Att were mostly remained attached 
but some became suspended. Similarly, suspended and semi-attached groups 
were mostly semi-attached but some attached after the additional culture
(Supplementary Fig. 1). Then, I checked expression of CD141 on the nine 
different subsets after the additional culture. The expression of CD141 was 
increased on the moDCs retaining adhesion to the plate bottom (att→att) (Fig. 
5B). The attached moDCs showed higher expression of surface CD141 than 
those of the others, attached cells derived from suspended (sus→att) and semi-
attached moDCs (sem→att) or non-attached cells derived from attached moDCs
(att→sem, att→sus). It suggested that attached property could affect expression 
of CD141. In addition, unlike other molecules (Supplementary Fig. 2), CD11c, 
CD86, PD-L1, PD-L2, and CCR1 were increased on attached moDCs (Fig. 5C). 
Especially, the expression of PD-L1, PD-L2, and CXCR4 are expressed on all 
the subsets which were not expressed at 8 days. These results suggested that all 
subsets after additional 3-day culture have potential of heterogeneity.
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Figure 5. Adhesive capacity is partially involved in CD141 expression of 
moDCs. CD14+ monocytes were treated with GM-CSF and IL-4 for 8 days. (A) 
Three types of moDCs, based on the attachment, were cultured separately for 
additional 3 days with media containing GM-CSF and IL-4. Then, nine 
different subpopulations were analyzed for (B) the expression of CD141 (C) 
CD11c, CD86, PD-L1, PD-L2, CCR1, and CXCR4 expression. Isotype control 
is shown as gray on each histogram. One representative result of at least three 
independent experiments is shown.
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5) Dead cell uptake and TLR3 response of attached CD141+ moDCs
To further characterize these moDCs, I examined the expression of CLEC9A
[5, 26], XCR1 [13, 14], TLR3 [3, 53], and CADM1 [5, 17] since they are highly
expressed on CD141+ DCs as previously reported. As shown in Figure 6A,
attached CD141+ moDCs partially expressed CLEC9A, XCR1, and TLR3 more 
than other subsets. Additionally, none of the subsets expressed CADM1.
It has been suggested that human CD141+ DCs expressed high levels of 
CLEC9A which specialized in antigen derived from dead cell uptake [12, 28]. It 
has been shown to mediate and enhance cross-presentation of dead cell-
associated antigens from viral infected of tumor cells [10, 26, 27]. Therefore, I
examined CFSE labeled-heat killed autologous PBMCs uptake by attached 
CD141+ moDCs. I observed that the percentage of attached CD141+ moDCs 
expressed CFSE was higher than other subsets (Fig. 6B). Therefore, attached 
CD141+ moDCs partially expressing CLEC9A (Fig. 6A) were efficiently uptake 
dead cells. 
Human CD141+ DCs specifically express high level of TLR3 and are 
triggered by synthetic ligand, poly I:C enhancing cross-presentation [13, 61, 62].
Next, the attached CD141+ moDCs were treated with polyI:C for 16 hrs. The 
results demonstrated that attached CD141+ moDCs matured phenotypically in 
response to poly I:C stimulation compared to the other subsets (Fig. 6C). In 
addition, IL-6 and IL-1β production by attached CD141+ moDCs treated with 
poly I:C was higher than other subsets (Fig. 6D). However, TNFα, IL-8, and IL-
10 secretion were not upregulated in attached CD141+ moDCs.
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Figure 6. Dead cell uptake and TLR3 response of attached CD141+ moDCs.
CD14+ monocytes were treated with GM-CSF and IL-4 for 8 days. Three types 
of moDCs, based on the attachment, were cultured separately for additional 3 
days with media containing GM-CSF and IL-4. (A) MFI of CLEC9A, XCR1, 
and TLR3 on each of the cell subsets. Results from three independent cultures 
for each DC subset are shown as individual line.
(B) The moDCs were incubated with CFSE-labeled heat killed (90℃, 30 min)
autologous PBMCs at 1:1 ratio as described in the Materials and Methods. 
Uptake of dead cells by moDCs was quantified by flow cytometry. (C) Fold 
change of MFI of costimulatory molecules CD80, CD83, CD86, and CD40 by 
the subsets after 16hr culture in media alone or in the presence of poly I:C. The 
fold change of MFI for at least three donors is shown as individual lines. To 
determine significance, one-way ANOVA followed by a Friedman test corrected 
by Dunn’s multiple comparison test was performed on twelve independent 
cultures from twelve different donors. *p<0.05, **p<0.01, ***p<0.001. (D) 
moDC subsets were stimulated with polyI:C (PIC). Culture supernatants were 
examined by using ELISA. Results from three independent cultures for each 
DC subset are shown as mean ± SEM.
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6) Allogeneic mixed lymphocyte reaction by attached CD141+ moDCs
One of important features of DCs is the ability to induce the proliferation of 
allogeneic T cells in a mixed lymphocyte reaction (MLR). In addition, CD141+
DCs are known as strong inducers of Th1 responses particularly after poly I:C 
stimulation [3, 16]. Interestingly, the results showed that the attached CD141+
moDCs induced neither differentiation nor activation (Fig. 7A) of allogeneic 
CD4+ T cells in the MLR. In addition, IL-2 and IFN-γ were not detected by all 
the subsets while IL-17 was observed exclusively in each group (Fig. 7B).
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Figure 7. Allogeneic MLR by attached CD141+ moDCs. Bead-sorted 
allogeneic CD4+ T cells, labeled with CTV, were co-cultured with unstimulated 
(-) or poly I:C (PIC) activated (+) moDCs, or in the absence of DC (no DC) for 
6 days. (A) CD4+ T cell proliferation by CTV dilution, and MFI of CD25 and 
CD69 was measured using flow cytometry. Results from at least five different 
samples are shown as mean ± SEM. (B) The supernatants were harvested and 
34
IL-2, IFN-γ, and IL-17 production was examined by using ELISA. Results from 
three independent cultures for each DC subset are shown as mean ± SEM.
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V. Supplementary results
Supplementary Fig. 1. The absolute number of nine different subsets after 
additional 3-day culture. CD14+ monocytes (1 x 107) were treated with GM-
CSF and IL-4 for 8 days. Three types of moDCs (1 x 106), based on the 
attachment, were cultured separately for additional 3 days with media 
containing GM-CSF and IL-4. Then, nine different subpopulations were 
analyzed for absolute numbers were examined. Results from at least ten
different samples are shown as mean ± SEM.
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Supplementary Fig. 2. Surface molecules of nine different subpopulations 
after additional 3-day culture Nine different moDC subsets were harvested 
and analyzed for the expression of surface molecules. Isotype control is shown 
in gray on each histogram. One representative result of at least three 
independent experiments is shown.
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VI. Discussion
CD141+ DCs are known to enhance cytotoxic T lymphocyte responses and, 
therefore, has been studied for the potential use of therapeutic vaccines against 
viruses [15, 63] and potentially cancers. However, they are rare in vivo 
consisting less than 0.03% in periphery in human [48, 64]. Thus, CD141+ DCs
differentiated in vitro has a high value to investigate. The current study 
demonstrated that immature CD141+ DCs could be generated in vitro from 
CD14+ monocytes in human peripheral blood mononuclear cells. It has been 
reported that in vitro derived CD141+ DCs obtained from human CD34+
hematopoietic progenitor of cord blood [5, 16]. However, CD141+ DCs from 
peripheral blood are better candidate for a therapeutic vaccine than those from 
cord blood because the former could be obtained consistently as needed in fresh 
condition. 
After the culture peripheral CD14+ monocytes for the generation of DCs, 
three different types of cells are observed depending on the ability to adhere to 
the culture plate. It has been demonstrated that suspended, loosely attached, and 
attached mouse bone marrow derived dendritic cells (BMDCs) cells exist after 
the culture [65, 66]. However, the characteristics of these subsets from human 
in vitro cultured moDCs are unknown. Since the loosely attached mouse 
BMDCs are reported as monocyte-derived macrophages expressed CD11c and 
MHC class II [65] and the attached BMDCs are divided into two populations, 
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MHCIIloF4/80hi macrophages and MHCIIhiF4/80lo DCs [66], I postulated that 
the attached or semi-attached moDCs can be macrophages or mixed cells 
containing macrophages and DCs. However, I found that all the subsets are not 
macrophages but immature moDCs and the attached moDCs expressed surface 
CD141 higher than those of the other subsets. This study is the first, at the best 
of our knowledge, describing the characteristics of subsets based on the 
attachment after the differentiation into moDCs.
Although the relationship between attachment and CD141 expression is
unclear from the previous studies, I postulate that the attached property may 
affect the expression of CD141. At this end, I purified attached moDCs and 
other subsets and then cultured for additional 3 days. It was noting that the
attached moDCs at 8 days are mostly remained the attached but some of them 
became suspended. In addition, moDCs maintained attached on the bottom of 
culture plate after additional 3-day culture expressed high level of CD141. It 
suggested that the attached property could affect the expression of CD141.
Additionally, I found that increase of CD141 on attached moDCs after 3-day 
culture was not affected by GM-CSF and IL-4 [67]. CD141 expression on 
attached moDCs after 3-day culture without these cytokines in media was not 
different from them cultured with the cytokines (data not shown). It suggested 
that it is not GM-CSF and IL-4 but other factors to increase CD141 on attached 
moDCs after 3-day culture.
On the other hand, the fact that human monocytes are divided into three types 
of subsets based on CD14 and CD16 could important to understand generation 
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of attached CD141+ moDCs [4, 34, 35]. According to previous studies, the 
subsets of monocytes could differentiate different types of DCs. For example, 
DCs in vitro generated from CD16+ monocytes expressed high level of CD86 
[68, 69]. In present study, there are approximately 6% of CD14+CD16+
monocytes in total CD14+ monocyte from PBMC (data not shown). Therefore, 
It needs to be further investigated that these monocytes subsets could associate 
with generation of attached CD141+ moDCs [34, 70]. Additionally, the recent 
studies show CD141+ DCs could differentiated from pre-conventional DCs 
(cDCs) in PBMC [31, 32]. It has been reported that human pre-cDCs are a 
mixture of cells committed to + moDCs either the CD141+ lineage (CD172a−
pre-cDCs) or the CD1c+ lineage (CD172a+ pre-cDCs) [31]. In addition, 
CD100+CD34int blood precursors gave rise to CD1c+ and CD141+ cDCs [32, 
71]. These studies can help to understand whether some pre-committed 
progenitors could be related with generation of attached CD141+ moDCs. It 
would be also interesting to determine whether some factors in culture 
environment including cell to cell interaction, cytokine and specific adhesion 
molecules from each cell influence the generation of attached CD141+ moDCs.
In conclusion, I suggested that immature CD141+ DCs could be generated in 
vitro from CD14+ monocytes in human peripheral blood, which could be further 
developed into the strategy to yield cross-priming human DCs in vitro. 
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VIII. Summary in Korean
인간 CD141+ 수지상 세포는 항원 교차 제시에 특화된 세포로, 수지상
세포를 기반으로 하는 암 치료를 위하여 널리 연구되었다. 체내에 극히 적
게 존재하는 현실적 한계를 극복하기 위하여 제대혈 유래 CD34+ 조혈 전
구세포로부터 CD141+ 수지상 세포를 생체 외 분화, 생성시키려는 시도들
이 있었으나, 여전히 이 세포를 생체 외에서 분화시키는 연구는 부족한 실
정이다.
본 연구는 CD141+ 수지상 세포가 일반적으로 단핵구 유래 수지상 세포
를 분화시키기 위해 사용하는 보편적인 배양방법에 의해서 생성이 가능하다
는 것을 보여준다. CD14+ 단핵구를 GM-CSF, IL-4 과 함께 8일 간 배
양하여 얻은 단핵구 유래 수지상 세포 중 일부는 배양 접시 바닥에 붙어 있
으며 이들은 CD141 발현이 특이적으로 높았다. 이 붙어 있는 세포들은 다
른 군집들에 비해 크기가 크고 가지를 많이 뻗고 있으며 CD86가 높게 발
현한다는 점을 제외하고는 전형적인 미성숙 단핵구 유래 수지상 세포의 특
성을 지닌다. CD141의 높은 발현은 추가 3일 배양 이 후에도 여전히 붙어
있는 세포에서 명확히 나타났으며 일부 CLEC9A를 발현하였다. 무엇보다
도, 이들은 죽은 세포를 효과적으로 인지하여 받아들이는 기능이 있음을 확
인할 수 있었다. 또한 흥미롭게도, polyI:C 처리에 대한 반응성과 동종 이
계 CD4+ T 세포와의 혼합림프구 반응에서 다른 군집과 반응성이 다른 것
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을 확인하였다.
종합적으로, 본 연구는 인간 말초 혈액 CD14+ 단핵구로부터 생체 외 배
양을 통하여 CD141+ 수지상 세포를 얻기 위한 앞으로의 연구에 기여 할
것임을 시사한다.
